OMS906 study drug

Phase 2

Omeros Corporation (OMER)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

OMERPhase 2$744M

OMS906 study drug Phase 2 Est. Readout

OMS906 study drug• Paroxysmal Nocturnal Hemoglobinuria25

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

3 competitors in Paroxysmal Nocturnal Hemoglobinuria

Drug Information

Target Indication

Paroxysmal Nocturnal Hemoglobinuria

Clinical Trial

NCT06298955

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

OMER

Omeros Corporation

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Phenylephrine HClPhase 3

Unilateral Cataract Extraction

OMS103HP-SPhase 3

Meniscal Tear

OMS103HPPhase 3

Anterior Cruciate Ligament Reconstruction

OMS302Phase 3

Intraocular Lens Replacement

OMS721Phase 2

Thrombotic Microangiopathies

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts